SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Idenix Pharmaceuticals, Inc. - IDIX
NEW YORK, June 13, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Idenix Pharmaceuticals, Inc. ("Idenix" or the "Company") (NASDAQ: IDIX) (ISIN: US45166R2040) (CUSIP: 45166R204) concerning the proposed acquisition of Idenix by Merck & Co.
Idenix shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at firstname.lastname@example.org or 212-661-1100 or 888-476-6529, ext. 237.
The investigation concerns whether the Idenix directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, each share of Idenix will be exchanged for $24.50 in cash.
Pomerantz LLP, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz LLP pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz LLP continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.
212-661-1100 ext. 237
SOURCE Pomerantz LLP